Hydrogen inhalation therapy alone may not alleviate intestinal mucosal damage in NOMI without total-layer necrosis: An experimental swine model study.
Yasutaka Tanaka, Yosuke Matsumura, Yosuke Hayashi, Makoto Aoki, Yoshimitsu Izawa, Kazuhiro Endo, Takashi Mato · Acute medicine & surgery · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This preclinical study evaluated hydrogen gas in an animal model. These results are preclinical and suggest that molecular hydrogen did not improve the measured outcome. Further human research is needed to determine its clinical relevance.
What the Researchers Studied
The study examined the researchers assessed the efficacy and feasibility of hydrogen inhalation therapy in swine models of critically ill conditions leading to non-occlusive mesenteric ischemia (NOMI) without acute surgical intervention.
How Molecular Hydrogen Was Used
The source material available to H2HUBB did not provide enough detail to identify the molecular hydrogen administration method.
What the Researchers Found
Control (n = 4) and hydrogen (n = 4) groups with similar baseline characteristics were included. At T = 240, lactate levels in the control and hydrogen groups were 7.4 (4.7-11.3) and 5.6 (5.0-6.4) mmol/L, respectively, while median 8-hydroxy-2'-deoxyguanosinelevels were 0.15 (0.14-0.18) and 0.15 (0.13-0.16) ng/mL.
H₂ Mechanisms / Biological Findings
Hydrogen inhalation therapy, a novel therapy for reducing oxidative stress in post-cardiac arrest syndrome, was beneficial for superior mesenteric artery (SMA) occlusion.
Authors’ Conclusion
The authors concluded that although critically ill conditions can trigger NOMI, the model used in this study did not involve transmural necrosis.